- Home
- FBIZ vs LYEL Comparison
FBIZ vs LYEL Comparison
Compare FBIZ & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBIZ | LYEL |
|---|---|---|
| Founded | 1909 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.9M | 490.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBIZ | LYEL |
|---|---|---|
| Price | $58.48 | $23.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $65.00 | $30.60 |
| AVG Volume (30 Days) | 36.0K | ★ 79.7K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $15.69 | N/A |
| Revenue Next Year | $8.47 | $16,285.34 |
| P/E Ratio | $9.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $45.61 | $0.39 |
| 52 Week High | $60.54 | $45.00 |
Technical Indicators
Market Signals| Indicator | FBIZ | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 55.91 |
| Support Level | $53.56 | $21.27 |
| Resistance Level | $59.60 | $27.30 |
| Average True Range (ATR) | 1.36 | 1.70 |
| MACD | 0.64 | 0.53 |
| Stochastic Oscillator | 86.02 | 75.83 |
Price Performance
Historical ComparisonAbout FBIZ First Business Financial Services Inc.
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.